CD markers

亜型選択性的な製品

CD38 CD45 CD39 CD11 CD88 CD73

CD markers製品

All (18)
CD markers阻害剤 (13)
CD markers拮抗剤(3)
CD markers作動薬(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2632	BMS-378806	BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.	Commun Biol, 2025, 8(1):442 Commun Biol, 2023, 6(1):535 J Virol, 2021, 95(24):e0052921
S8960	CD38 inhibitor 1 (compound 78c)	CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.	Leukemia, 2025, 10.1038/s41375-025-02551-4 J Nanobiotechnology, 2025, 23(1):457 Cell Rep Med, 2024, 5(2):101400
S5525	SodiuM Metatungstate	Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.	Cancer Immunol Immunother, 2024, 73(6):108 Immunology, 2022, 10.1111/imm.13493 Cancer Cell, 2021, 39(7):973-988.e9
S6239	PMX-53	PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).	Redox Biol, 2025, 86:103802 Biomolecules, 2025, 15(8)1106 Thromb J, 2022, 20(1):24
S0141	NQ301	NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.	J Extracell Vesicles, 2021, 10(5):e12078
S9867	LY-3475070	LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).	Theranostics, 2024, 14(3):1224-1240 Immunology, 2022, 10.1111/imm.13493
S0474	Avacopan	Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.	Br J Cancer, 2025, 10.1038/s41416-025-03185-0 Nat Commun, 2024, 15(1):6519 Cell Death Dis, 2022, 13(5):500
S3301	Cynarin	Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.	Int J Mol Med, 2025, 56(6)206
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
P1208	PMX 205 acetate	PMX 205 acetate is a cyclic hexapeptide that acts as a potent C5a receptor (C5aR, CD88) antagonist with an IC50 of 31 nM.	Ecotoxicol Environ Saf, 2025, 289:117627 Int Immunopharmacol, 2023, 125(Pt B):111112
E4693^New	AC-73	AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research.
S8908	AB680	AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73
E1276	MK-0159	MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
S7487	YYA-021	YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
E1305	RBN013209	RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
S6347	5'-N-Ethylcarboxamidoadenosine (NECA)	5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
S2632	BMS-378806	BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.	Commun Biol, 2025, 8(1):442 Commun Biol, 2023, 6(1):535 J Virol, 2021, 95(24):e0052921
S8960	CD38 inhibitor 1 (compound 78c)	CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.	Leukemia, 2025, 10.1038/s41375-025-02551-4 J Nanobiotechnology, 2025, 23(1):457 Cell Rep Med, 2024, 5(2):101400
S5525	SodiuM Metatungstate	Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.	Cancer Immunol Immunother, 2024, 73(6):108 Immunology, 2022, 10.1111/imm.13493 Cancer Cell, 2021, 39(7):973-988.e9
S0141	NQ301	NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.	J Extracell Vesicles, 2021, 10(5):e12078
S9867	LY-3475070	LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).	Theranostics, 2024, 14(3):1224-1240 Immunology, 2022, 10.1111/imm.13493
S3301	Cynarin	Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.	Int J Mol Med, 2025, 56(6)206
E4693^New	AC-73	AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research.
S8908	AB680	AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73
E1276	MK-0159	MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
S7487	YYA-021	YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
E1305	RBN013209	RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
S6347	5'-N-Ethylcarboxamidoadenosine (NECA)	5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
S6727	AX-024 HCl	AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.	Cell Rep Med, 2025, S2666-3791(25)00231-9
S6239	PMX-53	PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).	Redox Biol, 2025, 86:103802 Biomolecules, 2025, 15(8)1106 Thromb J, 2022, 20(1):24
S0474	Avacopan	Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.	Br J Cancer, 2025, 10.1038/s41416-025-03185-0 Nat Commun, 2024, 15(1):6519 Cell Death Dis, 2022, 13(5):500
P1208	PMX 205 acetate	PMX 205 acetate is a cyclic hexapeptide that acts as a potent C5a receptor (C5aR, CD88) antagonist with an IC50 of 31 nM.	Ecotoxicol Environ Saf, 2025, 289:117627 Int Immunopharmacol, 2023, 125(Pt B):111112
S0525	ADH-503 (GB1275)	ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.	Front Immunol, 2025, 16:1420325
E4693^New	AC-73	AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research.